Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Duchenne Muscular Dystrophy

In brief

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.

Key facts

Study ID
NCT04281485
Run by
Pfizer
People needed
114
Starts
2020-11-05
Expected to finish
2039-04-15
Last updated by the study team
2026-07-22

Who can join

Age: 4 and older, up to 7. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.